In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...
GlobalData on MSN1d
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500mThe transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
The proposed Biosecure Act as well as the diversification of American and European firms away from China are expected to help ...
The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...
Chinese cybersecurity regulator details on the lenient certification method for cross-border data transfer; U.S. issues final ...
The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...
Forecast: Pharma and healthcare mutual funds have topped with an average return of 38.05% in 2024. HDFC Pharma and Healthcare ...
JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth ...
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
The Biosecure Act was left out of a key US defence bill that passed in the House last week, in a major win for Chinese CDMOs. Shares in WuXi AppTec (Shanghai, China) opened 10.5% higher on ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback